The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties
Assessed by RV003 · Research Fellow
Assessed on 31 Oct 2025
OverallReviewer's overall integrity assessment, derived from all research questions Some concerns
DOI 10.1007/s13318-014-0242-5 (opens in new tab)
Resource ripekg:research-integrity-assessment/RIPEAD0800A4DFB9CD804
5 Research Questions · 2 Evidence Items
Q1.1 — Does the study have an associated retraction?
Rationale: No rationale provided
Q1.2 — Does the study have an associated expression of concern or other relevant post-publication notice?
Rationale: No rationale provided
Q1.3 — Do other studies by the research team highlight causes for concern?
Rationale: No rationale provided
Q2.2 — Are there concerns relating to the timing or absence of study registration?
Rationale: No details of recruitment dates or registration of study
Supporting Evidence (2)
Clinical Trial RegistrationSource: Clinical trial registry (e.g. ClinicalTrials.gov, ISRCTN)
No trial registration found
Assessment Rationale:How INSPECT-AI determined the prospective registration status by comparing dates LLM-extracted recruitment start date (normalized_date) is missing or empty.
Study Design EvidenceDates and timelines extracted by INSPECT-AI from the publication text
Recruitment Start: N/A
Recruitment Start Rationale:INSPECT-AI's reasoning for how it identified the recruitment start date No recruitment start date found.
Recruitment End: N/A
Recruitment End Rationale:INSPECT-AI's reasoning for how it identified the recruitment end date No recruitment finish date found.
Study End: N/A
Study End Rationale:INSPECT-AI's reasoning for how it identified the study end date No study end date found.
Overall — What is the overall integrity assessment of the study?
Rationale: Recruitment dates not reported. No details of study registration